《公司業績》再鼎醫藥(09688.HK)半年虧損收窄至1.7億美元
再鼎醫藥(09688.HK)公佈截至今年6月底止中期業績,根據美國公認會計準則,期內錄得營業額1.32億美元(下同),按年升38.7%。虧損收窄至1.7億元,上年同期蝕2.2億元;每股虧損18仙。
再鼎醫藥總裁兼首席運營官Josh Smiley表示,展望未來,公司在未來五年內有望實現收入的大幅增長和利潤率的提升。公司預計到2028年底將擁有超過15個商業化階段產品,並且每年至少提交一個潛在同類首創/同類最優產品管線的新藥臨牀研究申請。預計從2023到2028年,公司管線資產將推動公司保持超過50%的年均複合增長率。此外,公司預計到2025年年底有望實現盈利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.